Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613405 | 0.90 | KMT2A (0.49) | KMT2ACPB1CPB2 | |
| SCHEMBL29129196 | 0.90 | KMT2A (0.57) | KMT2AANPEP | |
| SCHEMBL29129191 | 0.90 | KMT2A (0.57) | KMT2AANPEP | |
| SCHEMBL29613497 | 0.89 | KMT2A (0.53) | KMT2AANPEP | |
| SCHEMBL13723619 | 0.88 | KMT2A (0.45) | KMT2AHDAC1HDAC2 | |
| SCHEMBL12880711 | 0.88 | KMT2A (0.61) | KMT2AANPEPDPP8DPP7HDAC1 | |
| SCHEMBL29613425 | 0.85 | KLK7 (0.52) | KMT2AHDAC1HDAC2 | |
| SCHEMBL23446480 | 0.85 | KMT2A (0.55) | KMT2AANPEPDPP8DPP7DPP4 | |
| SCHEMBL9933277 | 0.84 | HDAC1 (0.52) | KMT2AANPEPDPP8DPP7HDAC1 | |
| SCHEMBL9933279 | 0.84 | HDAC1 (0.52) | KMT2AANPEPDPP8DPP7HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | KMT2A 2132/4885ANPEP 3809/4885DPP8 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.